Form 10-Q · Quarterly report
Vertex Pharmaceuticals 10-Q, filed Nov 3, 2026
- Filed
- CIK
- 0000875320
- Accession no.
- 0000875320-26-000291
Summary
Vertex Pharmaceuticals reported third-quarter 2026 total revenues of $3.4 billion, up from $3.1 billion in the third quarter of 2025, and completed its acquisition of Crinetics Pharmaceuticals. The FDA approved CASGEVY for children two years and older with sickle cell disease or transfusion-dependent beta thalassemia, and Vertex said povetacicept is under priority review for adults with IgA nephropathy with a PDUFA target action date of November 30, 2026.
Key points
- Q3 2026 total R&D, AIPR&D, and SG&A expenses rose to $2.2 billion from $1.5 billion a year earlier, largely on about $500 million of compensation and transaction expenses related to the Crinetics acquisition.
- Vertex recorded $99.2 million of CASGEVY product revenues in Q3 2026, a 30% increase from Q2 2026 and more than a 400% increase from Q3 2025.
- More than 750,000 JOURNAVX prescriptions were filled in Q3 2026, and Vertex recorded $58.3 million of JOURNAVX product revenues.
- Vertex said it completed enrollment in the AMPLITUDE pivotal trial of inaxaplin for APOL1-mediated kidney disease and expects interim analysis data in early 2027.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion OVERVIEW We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have eight approved medicines: five that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, one that treats severe sickle cell disease (“SCD”) and transfusion dependent beta thalassemia (“TDT”), life shortening inherited blood disorders, one that treats moderate-to-severe acute pain, and one that treats acromegaly. We are also preparing for the anticipated launch of povetacicept, a potential treatment for IgA nephropathy (“IgAN”). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.